195 related articles for article (PubMed ID: 26951840)
1. Effect of olanzapine for breast cancer patients resistant to triplet antiemetic therapy with nausea due to anthracycline-containing adjuvant chemotherapy.
Sato J; Kashiwaba M; Komatsu H; Ishida K; Nihei S; Kudo K
Jpn J Clin Oncol; 2016 May; 46(5):415-20. PubMed ID: 26951840
[TBL] [Abstract][Full Text] [Related]
2. Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy.
Kosaka Y; Tanino H; Sengoku N; Minatani N; Kikuchi M; Nishimiya H; Waraya M; Katoh H; Enomoto T; Sato T; Kuranami M; Watanabe M
Support Care Cancer; 2016 Mar; 24(3):1405-11. PubMed ID: 26349772
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
Abe M; Hirashima Y; Kasamatsu Y; Kado N; Komeda S; Kuji S; Tanaka A; Takahashi N; Takekuma M; Hihara H; Ichikawa Y; Itonaga Y; Hirakawa T; Nasu K; Miyagi K; Murakami J; Ito K
Support Care Cancer; 2016 Feb; 24(2):675-682. PubMed ID: 26130365
[TBL] [Abstract][Full Text] [Related]
4. Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting.
Tanaka K; Inui N; Karayama M; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Kusagaya H; Matsuura S; Uto T; Hashimoto D; Matsui T; Asada K; Suda T
Cancer Chemother Pharmacol; 2019 Jul; 84(1):147-153. PubMed ID: 31087137
[TBL] [Abstract][Full Text] [Related]
5. Study protocol for a double-blind, comparative, randomised Japanese trial of triplet standard antiemetic therapies with or without 5 mg olanzapine to prevent chemotherapy-induced nausea and vomiting for patients with breast cancer treated with an anthracycline/cyclophosphamide regimen (JTOP-B).
Ozeki R; Iihara H; Shimokawa M; Hashimoto H; Abe M; Mukohara T; Bando H; Hayashi T; Kawazoe H; Komoda M; Yanai Takahashi T; Saito M
BMJ Open; 2022 Mar; 12(3):e058755. PubMed ID: 35236735
[TBL] [Abstract][Full Text] [Related]
6. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Hashimoto H; Abe M; Tokuyama O; Mizutani H; Uchitomi Y; Yamaguchi T; Hoshina Y; Sakata Y; Takahashi TY; Nakashima K; Nakao M; Takei D; Zenda S; Mizukami K; Iwasa S; Sakurai M; Yamamoto N; Ohe Y
Lancet Oncol; 2020 Feb; 21(2):242-249. PubMed ID: 31838011
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
8. Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy.
Ellebaek E; Herrstedt J
Curr Opin Support Palliat Care; 2008 Mar; 2(1):28-34. PubMed ID: 18685391
[TBL] [Abstract][Full Text] [Related]
9. Control of Nausea and Vomiting in Patients Receiving Anthracycline/Cyclophosphamide Chemotherapy for Breast Cancer.
Nawa-Nishigaki M; Kobayashi R; Suzuki A; Hirose C; Matsuoka R; Mori R; Futamura M; Sugiyama T; Yoshida K; Itoh Y
Anticancer Res; 2018 Feb; 38(2):877-884. PubMed ID: 29374715
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer.
Kusagaya H; Inui N; Karayama M; Fujisawa T; Enomoto N; Kuroishi S; Nakamura Y; Matsuda H; Yokomura K; Koshimizu N; Toyoshima M; Imokawa S; Yamada T; Shirai T; Hayakawa H; Suda T
Lung Cancer; 2015 Dec; 90(3):410-6. PubMed ID: 26791800
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting.
Clemons M; Dranitsaris G; Sienkiewicz M; Sehdev S; Ng T; Robinson A; Mates M; Hsu T; McGee S; Freedman O; Kumar V; Fergusson D; Hutton B; Vandermeer L; Hilton J
Breast; 2020 Dec; 54():278-285. PubMed ID: 33242754
[TBL] [Abstract][Full Text] [Related]
12. Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial.
Clemons M; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Segal R; Dent S; Gertler S; Song X; Wheatley-Price P; Dranitsaris G
JAMA Oncol; 2016 Feb; 2(2):225-31. PubMed ID: 26562292
[TBL] [Abstract][Full Text] [Related]
13. Olanzapine as antiemetic drug in oncology: a retrospective study in non-responders to standard antiemetic therapy.
Slimano F; Netzer F; Borget I; Lemare F; Besse B
Int J Clin Pharm; 2018 Oct; 40(5):1265-1271. PubMed ID: 29744791
[TBL] [Abstract][Full Text] [Related]
14. Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine.
Bosnjak SM; Dimitrijevic J; Djordjevic F
Curr Opin Support Palliat Care; 2016 Jun; 10(2):180-8. PubMed ID: 27028050
[TBL] [Abstract][Full Text] [Related]
15. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
[TBL] [Abstract][Full Text] [Related]
16. A pooled analysis of adding olanzapine to guideline-recommended antiemetic therapy for breast cancer patients treated with an anthracycline and cyclophosphamide in prospective and retrospective studies.
Xiao BY; Su T; Huang YJ; Lin GH; Liu ZB; Tang YX; Wang BC
Support Care Cancer; 2022 Mar; 30(3):2445-2453. PubMed ID: 34775535
[TBL] [Abstract][Full Text] [Related]
17. Effective Antiemetic Therapy Is Important With Adjuvant Anthracycline-based Chemotherapy in Breast Cancer.
Takala L; Bärlund M; Kellokumpu-Lehtinen PL
Anticancer Res; 2019 Jan; 39(1):279-283. PubMed ID: 30591469
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Olanzapine Combined Therapy for Patients Receiving Highly Emetogenic Chemotherapy Resistant to Standard Antiemetic Therapy.
Abe M; Kasamatsu Y; Kado N; Kuji S; Tanaka A; Takahashi N; Takekuma M; Hirashima Y
Biomed Res Int; 2015; 2015():956785. PubMed ID: 26425564
[TBL] [Abstract][Full Text] [Related]
19. Genetic Risk Factors Associated With Antiemetic Efficacy of Palonosetron, Aprepitant, and Dexamethasone in Japanese Breast Cancer Patients Treated With Anthracycline-based Chemotherapy.
Yokoyama S; Tamaru S; Tamaki S; Nakanishi D; Mori A; Yamakawa T; Ao T; Sakata Y; Mizuno T; Iwamoto T; Watanabe K; Simomura M; Kawakami K; Konishi N; Kageyama S; Ohtani S; Yamada T; Ban S; Ooi K
Clin Breast Cancer; 2018 Apr; 18(2):e157-e165. PubMed ID: 28735677
[TBL] [Abstract][Full Text] [Related]
20. Incidence of nausea and vomiting in breast cancer patients treated with anthracycline plus cyclophosphamide-based chemotherapy regimens in Italy: NAVY observational study.
De Laurentiis M; Bonfadini C; Lorusso V; Cilenti G; Di Rella F; Altavilla G; Otero M; Ardizzoia A; Marchetti P; Peverelli G; Amoroso D; Vecchio S; Fiorio E; Orecchia S
Support Care Cancer; 2018 Dec; 26(12):4021-4029. PubMed ID: 29943152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
